Stoneridge Investment Partners’s NanoViricides NNVC Stock Holding History

Stoneridge Investment Partners’s Portfolio NNVC Stock Details NNVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,570	Closed	-$108K	–	310
2015 Q4	$108K	Sell	4,570 -754	-14%	-$18.1K	0.01%	271
2015 Q3	$127K	Sell	5,324 -300	-5%	-$7.94K	0.02%	272
2015 Q2	$195K	Buy	5,624 +1,615	+40%	+$61.5K	0.02%	262
2015 Q1	$180K	Buy	4,009 +151	+4%	+$8.05K	0.02%	249
2014 Q4	$210K	Buy	3,858 +813	+27%	+$53.8K	0.03%	236
2014 Q3	$183K	Buy	+3,045	New	+$239K	0.03%	227

Other funds holding NNVC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stoneridge Investment Partners's NNVC Position: Q1 2016 in Review

Stoneridge Investment Partners sold out of NanoViricides (NNVC) in Q1 2016, closing a stake of 4,570 shares — an estimated $108K sold.

Stoneridge Investment Partners first reported a position in NNVC in Q3 2014 and held it in 6 quarters. The position peaked at $210K in Q4 2014. 55 funds tracked by Wall St. Rank hold NNVC as of Q1 2016.

Stoneridge Investment Partners reported no remaining NanoViricides position as of Q1 2016 after selling out during the quarter.
Stoneridge Investment Partners sold 4,570 NanoViricides shares in Q1 2016, an estimated $108K.
Stoneridge Investment Partners first reported a position in NanoViricides in Q3 2014 and held it in 6 quarters.
Stoneridge Investment Partners's NanoViricides position peaked at $210K in Q4 2014.
55 funds tracked by Wall St. Rank held NanoViricides as of Q1 2016.

Based on Stoneridge Investment Partners's 13F filing for Q1 2016, filed 29 Apr 2016.